Compass Pathways Plc (CMPS)
Featured in
High-Beta Momentum
Compass Pathways plc is a biotechnology company focused on mental health research in the United Kingdom and the United States. Through its listed ADR on NASDAQ, the company is developing COMP360, a psilocybin therapy candidate being studied in Phase III clinical trials for treatment-resistant depression and in Phase II trials for post-traumatic stress disorder and anorexia nervosa. The business was formerly known as COMPASS Rx Limited and adopted the Compass Pathways plc name in August 2020. Incorporated in 2020, the company is headquartered in London, United Kingdom.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CMPS
|
$13.88
|
-8.6% Downside
|
Fair
|
$23.75
|
56.4% Upside
|
Bargain
|
Weak
|
0.0%
|
October 29, 2026
|
24.9x
|
2.103 B
|
1.725 B
|
2.6%
|
77.2%
|
-4.0
|
40.9%
|
